Execution of Loan Facility Agreement
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Argent Biopharma Ltd has announced the execution of two loan facility agreements with specific lenders, totaling a significant funding amount for the company. The proceeds from these loans will be utilized for working capital, corporate costs, and research and development activities. Key terms include a repayment term and conditions related to capital raises, with the loans being unsecured and subject to specific interest rates on overdue amounts.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Argent Biopharma
- Argent Signs NLC Licence to Expand Antiviral Portfolio
- Appendix 4E and 2026 Annual Report
- FDA-CVM Establish INAD File for CannEpil Veterinary Program
- US Veterinary Development Programme for CannEpil Commences
- CannEpil Global Licence Expands into Veterinary Healthcare
Later from Argent Biopharma
- Quarterly Activities/Appendix 4C Cash Flow Report
- RGT Executes Global Licence for Non-Core Cannabis Genetics
Follow Argent Biopharma into a list and get an email when it puts out news.
Follow Argent Biopharma